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The cytokine interleukin-6 (IL-6) is known as a growth factor in
malignant melanoma (MM), stimulating tumour cells to prolif-
erate (Kishimoto and Akira, 1992; Lee et al, 1992; Candi et al,
1997). Recently, a homologe to the human IL-6 has been identified
in the human herpesvirus-type 8 (HHV-8) genome (Neipel et al,
1997). HHV-8 is a gamma-herpesvirus, related to the tumourigenic
Epstein–Barr virus and herpesvirus saimiri and was first identified
in AIDS-associated Kaposi’s sarcoma (KS) in 1994 (Chang et al,
1994). HHV-8 has been detected consistently in HIV-related and
HIV-unrelated cases of KS, but also in body cavity B-cell
lymphomas and multicentric Castleman’s disease (Cesarman et al,
1997; Nicholas et al, 1997). HHV-8-encoded IL-6 homologue
(vIL-6) is the first known example of an IL-6-type gene in a viral
genome (Neipel et al, 1997). The receptor binding region is highly
conserved, and vIL-6 shares biological activities with human IL-6
protein (Nicholas et al, 1997).
The presence of a IL-6 homologue encoded by HHV-8 actually
provides a mechanistic model for the hypothesized role of
HHV-8 in KS, body cavity B-cell lymphomas and multicentric
Castleman’s disease, that involves the mitogenic effects of vIL-6
on surrounding cells. Transmitting this model to other tumours
known to be stimulated by IL-6, the hypothesis was formulated
that MM might also harbour HHV-8.
We therefore sought to identify HHV-8 DNA in melanoma
tissue. Using a specific and highly sensitive polymerase chain
reaction (PCR) protocol to amplify DNA of the viral minor capsid
protein gene, we evaluated genomic DNA samples from 33
primary MMs for the presence of HHV-8 DNA.
MATERIAL AND METHODS
Isolation of genomic DNA from paraffin-embedded
tissue
Genomic DNA was isolated from paraffin-embedded tissue from
45 MMs. All tumours were diagnosed with at least a thickness
according to Breslow of 1.5 mm and Clark’s level IV. Isolation of
DNA was performed using the High Pure PCR template prepara-
tion kit (Boehringer Mannheim, Mannheim, Germany) according
to the manufacturer’s instructions. Quality of isolated DNA was
assessed by 1% agarose gel electrophoresis.
Polymerase chain reaction
PCR was performed as described (Corbellino et al, 1996). HHV-8
DNA was amplified using primer pair 087se/088as (Corbellino
et al, 1996), and 1 ml of the PCR products was amplified in nested
PCRs, using primer pair KS330se/KS330as (Chang et al, 1994,
Figure 1). DNA specimens from three Kaposi’s sarcoma (KS)
served as positive controls, water as negative controls. The
absence of major Taq polymerase inhibitors, as well as DNA
integrity in the tissue samples, were assessed by PCR amplifica-
tion of a 268 bp human b-globin gene fragment, using the primers
GH20 and PC04 (Greer et al, 1991). PCR products were analysed
by 1.8% agarose gel electrophoresis.
Sequencing of PCR products
KS330se/KS330as PCR products of 233 base pair (bp) length
from KS tissue were separated electrophoretically on 1.8%
agarose gel and purified with Qiaex II gel extraction columns
(Qiagen, Chatsworth, CA, USA). DNA fragments (50–100 ng)
were sequenced with Cycle Sequencing 9700 PE (Applied
Biosystems, Foster City, CA, USA) using primers KS330se and
KS330as respectively (Smith et al, 1986; Medigene, Martinsried,
Germany). The samples were analysed with the ABI Prism 377
Genetic Analyzer (Perkin-Elmer). Sequences of PCR products
were compared with HHV-8 DNA (EMBL data bank accession
number KSV18551) using the softwares Clustal and BESTfit of
the Heidelberg Unix Sequence Analysis Resources (HUSAR,
version 4.0, DKFZ, Heidelberg).
Sensitivity of the PCR assay
A 983 bp DNA fragment from KS DNA samples was ampli-
fied using primer pairs KS636se/KS1743as in a first and
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Correspondence to: M DeichmannKS730se/KS1713as in a nested PCR (Figure 1). The sequences of
the primers were: KS636se 5¢-GCA CTC GAC AAG AGT ATA
GTG G-3¢; KS1743se 5¢-ATA TCC ACG ATC CCG TCG CTG
A-3¢; KS730as 5¢-TCG GAG ATT GCC ACC GTT TAC A-3¢; KS
1713 as 5¢-TCT TTG ATG GCG TCG GTC TCT A-3¢. Numbers
in the primers’ designations are derived from HHV-8 minor capsid
protein nucleotide sequence (Chang et al, 1994). PCR solutions
and cycle conditions were the same as described (Corbellino et al,
1996). The 087se/088as spanning DNA fragment was cleaned
using High Pure filter tubes (Boehringer Mannheim) according to
the manufacturer’s recommendations, measured by photometer
five independent times and serially diluted. Solutions containing
25, 10, 5, 2, 1, one-quarter, one-eight and one-sixteenth copies of
the 983 bp DNA fragment were assessed by the PCR assay used
for HHV-8 DNA detection in melanomas.
RESULTS
Before assessing melanoma DNA samples for the presence of
HHV-8 DNA, size and quantity of isolated DNA were estimated
by agarose gel electrophoresis, and the presence of amplifiable
DNA was assessed by PCR amplification of a 268 bp human
b-globin gene fragment. Thirty-three of 45 melanoma DNA
samples (ten nodular melanomas, 15 superficial spreading
melanomas, four acrolentiginous melanomas, two lentigo maligna
melanomas, two subcutaneous metastases) were positive in globin
PCR, and positive results in globin PCR were in accordance with
agarose gel electrophoresis showing high molecular integrity of
DNA.
Following globin PCR, melanoma DNA samples were assessed
for the presence of HHV-8 DNA using primer pairs 087se/088as in
a first, and KS330se/KS330as in a nested PCR to amplify a 232
base pair DNA fragment of the HHV-8 minor capsid protein gene.
None of 33 melanoma DNA samples contained HHV-8 DNA
(Figure 2). Assessing KS biopsies, all three DNA specimens were
positive in HHV-8 PCR. Several water controls were all negative
for HHV-8 DNA.
To confirm that HHV-8-DNA, but no related sequences, were
amplified in the PCR reactions, cycle sequencing of PCR products
was performed. The sequence of HHV-8 PCR products was deter-
mined for 230 nucleotides, which were identical with the HHV-8
DNA sequence from position 989 to 1219 (EMBL data bank
accession no. KSV 18551).
To estimate the sensitivity of the PCR protocol used for
melanoma testing, a DNA fragment spanning the 087se and 088as
primer binding sites was synthesized from KS DNA samples.
Diluting this 983 bp DNA fragment, even a single copy was
detected by the HHV-8 PCR assay used for melanoma investiga-
tion (Figure 3). None of higher dilutions, e.g. one-quarter, one-
eighth, and one-sixteenth copy of HHV-8 DNA, was positive in
the HHV-8 PCR assay, making incorrect dilution unlikely.
DISCUSSION
The recent identification of a vIL-6 gene in the HHV-8 genome
suggested a putative role of this virus in the pathogenesis of MM:
human melanoma cells have been reported to express IL-6 at
mRNA and in part at protein level in vitro (Colombo et al, 1992;
Lee et al, 1992; Francis et al, 1996). In addition, elevated IL-6
serum levels in patients with metastatic melanoma have been asso-
ciated with resistance to immunotherapy and shorter median
survival (Tartour et al, 1994, 1996) and are related to progressive
disease (unpublished data). In accordance with these data, infec-
tion of melanoma cells by HHV-8 and transcription of vIL-6 was
hypothesized to enhance MM tumour cell proliferation.
However, assessing genomic DNA samples from histologically
proven MMs by a specific and highly sensitive PCR assay, HHV-8
DNA was not detected in any of 33 samples. The tumours were not
investigated for IL-6 expression, which was assumed according to
previous reports (Lee et al, 1992; Candi et al, 1997). We therefore
conclude that melanoma tumour cell proliferation is unlikely to
be enhanced by vIL-6 from HHV-8 infection. In the same way,
elevated IL-6 serum levels related with progressive disease in
metastasized patients are probably not caused by HHV-8 cytokine
expression. Secretion of this protein more likely reflects acute-
phase reaction caused by tumour disease, since IL-6 is known as a
major molecular mediator of inflammatory conditions. IL-6 is
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Figure 1 Position of HHV-8-specific primers. The primer pair 087se/088as
was used in a first and KS330se/KS330as in a nested PCR to investigate
malignant melanoma DNA samples for the presence of HHV-8 DNA. The
primer pair 636se/1743as was used in first and 730se/1713as in a nested
PCR to synthesize high amounts of a 087se/088as spanning DNA fragment
from the HHV-8 genome in Kaposi’s sarcoma. Serially dilutions of this DNA
fragment were assessed by the PCR assay used for melanoma investigation
to estimate the sensitivity of this assay
Globin
HHV-8 —232 bp
—260 bp
water 1
water 2
KS 1
MM 1
KS 2
MM 2
MM 3
KS 3
Figure 2 HHV-8 DNA is not detected in malignant melanomas. Globin and
HHV-8 PCR are shown one below another. Water served as negative
controls, three Kaposi’s sarcoma DNA specimens as positive controls (KS).
In addition to the PCR results from three melanomas in this experiment (MM),
30 further tumours were tested negative
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Figure 3 Even a single copy of HHV-8 DNA was detected by the PCR
protocol used for melanoma investigation. A DNA fragment spanning the
087se and 088as primer binding sites was synthesized, measured in quantity
and serially diluted. Solutions containing 25, 10, 5, 2 and a single copy of this
DNA fragment gave positive results in the HHV-8 PCR assay, whereas
solutions expecting one-quarter, one-eighth and one-sixteenth copy on
average were negative. Water served as negative controlsproduced by a variety of cells including fibroblasts, endothelial
cells, keratinocytes, T and B lymphocytes and macrophages
(Kishimoto, 1989; Klein et al, 1989).
Similar to malignant melanoma, IL-6 has been reported as an
autocrine growth factor in KS and in multiple myeloma (Akira and
Kishimoto, 1992; Suzuki et al, 1992), and elevated serum-IL-6
levels in multiple myeloma were associated with high tumour
burden and with poor prognosis (DuVillard et al, 1995; Pelliniemi
et al, 1995). Indeed, HHV-8 has been found in both diseases:
HHV-8 was first detected in KS tissue (Chang et al, 1994) and has
recently been identified in bone marrow from patients with
multiple myeloma (Rettig et al, 1997; Said et al, 1997). HHV-8
encoded vIL-6 was transcribed in the myeloma bone marrow
dendritic cells and therefore may be required for the growth of
malignant plasma cells (Rettig et al, 1997). However, the role of
HHV-8 in the pathogenesis of multiple myeloma remains contro-
versial, as HHV-8 DNA was not found in mobilized blood
mononuclear cells of patients with multiple myeloma (Cull et al,
1998).
In conclusion, IL-6 acts as an autocrine growth factor in MM
similar to KS and multiple myeloma but is not of HHV-8 origin.
Since this herpesvirus was recently detected, and is the first known
example of a virus encoding a structural equivalent of IL-6 (Neipel
et al, 1997), further viruses related to the tumourigenic gamma-
herpesviruses known today will probably be identified and should
be investigated for involvement in malignant melanoma and other
tumours.
ACKNOWLEDGEMENTS
The authors thank W Hartschuh for histologic evaluation of the
malignant melanomas.
REFERENCES
Akira S and Kishimoto T (1992) The evidence for interleukin-6 as an autocrine
growth factor in malignancy. Semin Cancer Biol 3: 17–26
Candi E, Knight RA, Spinedi A, Guerrieri P and Melino G (1997) A possible growth
factor role of IL-6 in neuroectodermal tumours. J Neurooncol 31: 115–122
Cesarman E and Knowles DM (1997) Kaposi’s sarcoma-associated herpesvirus, a
lymphotropic human herpesvirus associated with Kaposi’s sarcoma, primary
effusion lymphoma, and multicentric Castleman’s disease. Semin Diagn Pathol
14: 54–66
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM and Moore PS
(1994) Identification of herpesvirus-like DNA sequences in AIDS-associated
Kaposi’s sarcoma. Science 266: 1865–1869
Colombo MP, Maccalli C, Mattei S, Melani C, Radrizzani M and Parmiani G (1992)
Expression of cytokine genes, including IL-6, in human malignant melanoma
cell lines. Melanoma Res 2: 181–189
Corbellino M, Poirel L, Bestetti G, Pizutto M, Aubin JT, Capra M, Bifulco C, Berti
E, Agut H, Rizzardini G, Galli M and Parravicini C (1996) Restricted tissue
distribution of extralesional Kaposi’s sarcoma herpesvirus-like DNA sequences
in AIDS patients with Kaposi’s sarcoma. AIDS Res Hum Retroviruses 12:
651–657
Cull GM, Timms JM, Haynes AP, Russel NH, Irving WL, Ball JK and Thomson BJ
(1998) Dendritic cells cultured from mononuclear cells and CD34 cells in
myeloma do not harbour human herpesvirus 8. Br J Haematol 100: 793–196
DuVillard L, Guiguet M, Casasnovas RO, Caillot D, Monnier-Zeller V, Bernard A,
Guy H and Solary E (1995) Diagnostic value of serum IL-6 level in
monoclonal gammopathies. Br J Hematol 89: 243–249
Francis GM, Krohn EG, Woods KV, Buzaid AC and Grimm EA (1996) Interleukin-6
production and secretion in human melanoma cell lines, regulation by
interleukin-1. Melanoma Res 6: 191–201
Greer CE, Peterson SL, Kiviat NB and Manos MM (1991) PCR amplification from
paraffin-embedded tissues, effects of fixative and fixation time. Am J Clin
Pathol 95: 117–124
Kishimoto T (1989) The biology of interleukin-6. Blood 74: 1–10
Kishimoto T and Akira S (1992) Interleukin-6 and its receptor, a paradigm for
cytokines. Science 258: 593–597
Klein B, Zhang XG, Jourdan B, Content B, Content J, Houssiau F, Aarden L,
Piechaczyk M and Bataille R (1989) Paracrine rather than autocrine regulation
of myeloma-cell growth and differentiation by interleukin-6. Blood 73:
517–526
Lee JD, Sievers TM, Skotzko M, Chandler CF, Morton DL, McBride WH and
Economou JS (1992) Interleukin-6 production by human melanoma cell lines.
Lymphokine-Cytokine-Res 11: 161–166
Neipel F, Albrecht JC, Ensser A, Huang YQ, Li JJ, Friedman-Kien AE and
Fleckenstein B (1997) Human herpesvirus 8 encodes a homolog of interleukin-
6. J Virol 71: 839–842
Nicholas J, Ruvolo VR, Burns WH, Sandford G, Wan X, Ciufo D, Hendrickson SB,
Guo HG, Hayward GS and Reitz MS (1997) Kaposi’s sarcoma-associated
human herpesvirus-8 encodes homologues of macrophage inflammatory
protein-1 and interleukin-6. Nat Med 3: 287–292
Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Fajamaki A, Tienhaara A, Laakso M
and Lahtinen R (1995) Immunoreactive interleukin-6 and acute phase proteins
as prognostic factors in multiple myeloma, Finnish leukemia group. Blood 85:
765–771
Rettig MB, Ma HJ, Viscio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo
C, Wu C, Fraser J, Said JW and Berenson JR (1997) Kaposi’s sarcoma-
associated herpesvirus infection of bone marrow dendritic cells from multiple
myeloma patients. Science 276: 1851–1854
Said JW, Rettig MR, Heppner K, Vescio RA, Schiller G, Ma HJ, Belson D, Savage
A, Shintaku IP, Koeffler HP, Asou H, Pinkus G, Pinkus J, Schrage M, Green E
and Berenson JR (1997) Localization of Kaposi’s sarcoma associated
herpesvirus in bone marrow biopsy samples from patients with multiple
myeloma. Blood 90: 4278–4282
Smith LM, Sanders JZ, Kaiser RJ, Hughes P, Dodd C, Connell CR, Heiner C, Kent
SBH and Hood LE (1986) Fluorescence detection in automated DNA
sequencing analysis. Nature 321: 674–679
Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T and
Kishimoto T (1992) Anti-human interleukin-6 receptor antibody inhibits
human myeloma growth in vivo. Eur J Immunol 22: 1989–1993
Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux
I, Pouillart P and Fridman WH (1994) Serum interleukin 6 and C-reactive
protein levels correlate with resistance to IL-2 therapy and poor survival in
melanoma patients. Br J Cancer 69: 911–913
Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, Deneux L, Gorin
I, Negrier S, Mathiot C, Pouillart P and Fridman WH (1996) Predictors of
clinical response to interleukin-2-based immunotherapy in melanoma patients,
a French multiinstitutional study. J Clin Oncol 14: 1697–1703
HHV-8 is not involved in malignant melanoma 69
British Journal of Cancer (1999) 80(1/2), 67–69 © Cancer Research Campaign 1999